Teleflex Incorporated reports developments for a global medical technology business that supplies hospitals and healthcare providers with devices used in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Its established brands include Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck.
Recurring Teleflex news covers quarterly financial results, outlook updates, revenue trends by global product category, portfolio realignment and integration of acquired vascular intervention assets. Company updates also include governance and leadership changes, board committee matters, capital allocation actions, shareholder communications and operational initiatives such as integrated demand and supply planning.
Quantum Computing Inc (Nasdaq: QUBT) announced an oversubscribed private placement of 26,867,276 shares priced at market to raise approximately $500 million gross. The company said the offering includes participation by several large existing shareholders and a first-time investment from a global alternative asset manager. The closing is expected on or about September 24, 2025, subject to customary conditions. The company intends to use net proceeds for commercialization, strategic acquisitions, sales and engineering hires, working capital, and general corporate purposes. The securities have not been registered under the Securities Act; the company agreed to file a resale registration statement. The company reported total gross capital raised since November 2024 of approximately $900 million and an expected post-close cash position of about $850 million.
Teleflex (NYSE: TFX) management will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 10:00 a.m. GMT.
A live audio webcast of the presentation will be available on Teleflex's investor website at teleflex.com.
Teleflex (NYSE: TFX) declared a quarterly cash dividend of $0.34 per share. The dividend is payable on December 15, 2025 to shareholders of record at the close of business on November 14, 2025.
This announcement sets the payment and record dates for the next quarterly distribution to common shareholders.
Teleflex (NYSE: TFX) reported third-quarter 2025 results: GAAP revenue $913.0M (+19.4% YoY) and adjusted revenue $892.9M (+16.8% YoY). GAAP diluted EPS from continuing operations was $(9.24) versus $2.36 prior year; adjusted diluted EPS was $3.67 versus $3.49 prior year. The company narrowed full-year 2025 GAAP revenue growth guidance to 9.10%–9.60%, lowered adjusted constant currency revenue growth to 6.90%–7.40%, cut GAAP EPS guidance to $(4.42)–$(4.22) and narrowed adjusted EPS to $14.00–$14.20.
Notable items: $403.9M goodwill impairment (Interventional Urology), $100M Titan SGS impairment, total impairments ~$512.0M, cash $381.3M, inventories $802.5M, and a Vascular Intervention integration plan with $36–44M restructuring costs and expected annual savings of $24–30M.
Teleflex (NYSE:TFX) will hold its Q3 2025 earnings conference call on Thursday, November 6, 2025 at 8:00 a.m. ET to discuss third-quarter results and provide an operational update. Participants should pre-register to receive dial-in information; a live audio webcast will be available at teleflex.com. An audio replay begins at 11:00 a.m. ET on November 6, 2025 and is accessible via the website or by phone at 1 800 770 2030 (U.S./Canada) or 1 609 800 9909 (international) using conference ID 69028.
Teleflex will also host a Vascular Intervention virtual investor meeting on November 14, 2025 at 8:00 a.m. ET to review its recent Vascular Intervention acquisition and product portfolio; pre-registration and a live webcast are available at teleflex.com.
Teleflex (NYSE:TFX) has initiated the DUBSTENT DIABETES trial with the enrollment of its first patient. This randomized, investigator-initiated clinical study aims to evaluate a dual-device strategy for percutaneous coronary intervention (PCI) in diabetic patients.
The trial will compare three approaches: a combination of Pantera Lux DCB Catheter with Orsiro Mission DES, Pantera Lux DCB alone, and Orsiro Mission DES alone. The study will enroll 120 diabetes patients across Irish centers, with primary endpoints measuring diameter stenosis at six months and secondary endpoints tracking various cardiac events over five years.
Teleflex (NYSE:TFX) announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The presentation is scheduled for Tuesday, September 9, 2025, at 3:20 p.m. ET at the Sheraton New York Times Square. Investors can access the live audio webcast through the company's investor relations website at teleflex.com.
Teleflex (NYSE:TFX) has launched its Barrigel™ rectal spacer in Japan following regulatory approval from the Japanese PMDA. The product is a non-animal stabilized hyaluronic acid spacer designed to reduce rectal radiation exposure during prostate cancer radiation therapy.
Clinical data shows 98% of patients achieved at least a 25% reduction in radiation to the rectum, with average reductions of 85% in rectal V54 Gy radiation. The launch is particularly significant as prostate cancer was Japan's most common cancer among men in 2022, with 104,318 new cases, representing 18% of all cancer diagnoses in the country.
Initial cases have already commenced in Japan under the direction of Dr. Jun Itami, with the product now available for immediate purchase following insurance coverage acceptance.
Teleflex (NYSE:TFX) has announced its latest quarterly dividend. The company's Board of Directors has declared a cash dividend of $0.34 per share of common stock. The dividend will be paid on September 15, 2025, to shareholders who are on record as of August 15, 2025.
Teleflex (NYSE:TFX) reported strong Q2 2025 financial results, with GAAP revenue reaching $780.9 million, up 4.2% year-over-year, and adjusted constant currency growth of 1.0%. The company achieved GAAP diluted EPS from continuing operations of $2.77 and adjusted diluted EPS of $3.73.
Following the successful acquisition of BIOTRONIK's Vascular Intervention business, Teleflex raised its 2025 guidance, now expecting GAAP revenue growth of 9.00% to 10.00% and adjusted constant currency revenue growth of 7.70% to 8.70%. The company also increased its adjusted diluted EPS guidance to $13.90-$14.30.
By segment, Americas revenue grew 1.9%, EMEA increased 13.0%, and Asia rose 2.3% in Q2. The Interventional category showed the strongest performance with 20.4% growth, while OEM and Interventional Urology experienced declines of 11.4% and 8.1% respectively.